Gene-edited cell therapy for beta-thalassemia: long-term safety check begins
NCT ID NCT06685536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 5 people with beta-thalassemia who already received an experimental gene-edited cell therapy called CS-101. Researchers will monitor them for years to see if the treatment remains safe and whether they can stay free from blood transfusions for at least 12 months. No new treatment is given in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How does a blood disorder drug perform in everyday practice?
- Newborn screening study aims to catch rare diseases at birth
- New stem cell transplant aims to ease severe blood disorders
- Gene-Editing breakthrough offers hope for blood disorder patients
- New stem cell transplant could help sickle cell patients without a perfect donor match
- New pill could help kids with thalassemia fight anemia without transfusions